Access, Ideas, Clarity
A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders
What This Means:
This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
April 25, 2024
The Annamycin Opportunity
April 25, 2024
March 15, 2024
ReElement Technologies' Certificate of Occupancy for Marion, Indiana Critical Mineral Refining Supersite
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial
February 29, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 3 of 3)
February 15, 2024
February 22, 2024
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 2 of 3)
A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 1 of 3)
February 12, 2024
Xenetic Biosciences Highlights Encouraging Recently Reported Preclinical Data on Innovative DNase I Oncology Platform
January 31, 2024
$8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use –
Over 100 patents in portfolio
February 09, 2024
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
_Logo_HOR.png){kind=logo}
January 29, 2024
Palisade Bio Reports Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress
January 9, 2024
American Resources Corporation's ReElement Technologies Adds Former United States Ambassador Mark Gilbert to Board of Directors
January 4, 2024
Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a
Business Overview
January 3, 2024
American Resources Corporation's ReElement Technologies Adds Former CIA Senior Executive Kevin Higgins to Board of Directors
December 5, 2023
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")
December 21, 2023
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
November 27, 2023
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023
FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
November 20, 2023
Next Generation Anthracycline
November 14, 2023
Full Enrollment for VenoValve U.S. Pivotal Trial
November, 1, 2023
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
October, 30, 2023
NKGen Biotech Receives FDA Clearance of IND for SNK01 NK Cell Therapy to Treat Moderate Alzheimer's Disease
October, 18, 2023
Continuing Rapid Pace of
Enrollment with 229 Patients Enrolled
October, 17, 2023
Moleculin Doses First Patient in
Phase 2 Study for AML
September 27, 2023
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement.
September 8, 2023
AREC's ReElement Technologies Expands Executive Team
August 24, 2023
Recent Clinical Update on Potentially Pivotal Study of Berubicin for GBM
GRI Bio Enters into Asset Purchase Agreement for Sale of Legacy Asset, ADAIR
August 23, 2023
August 7, 2023
GRI Bio Presents Encouraging Preclinical Data of GRI-0803 in Lupus Nephritis